- Home
- Companies
- Regeneus Ltd.
- Articles
Regeneus Ltd. articles
Q. What is your background and experience in the regenerative medicine and stem cell space? How did this lead you to Regeneus?
A. I’d always had a love for medical research, however found myself working in the pharmaceutical industry after university prior to joining Regeneus. After 6 years in the pharma industry, I’d decided I needed to get back to a research focused career. The timing was perfect when I saw an opening at Regeneus in 2013. Sinc
After being awarded the MTPConnect REDI Fellowship Grant in August 2020, Postdoctoral Research Fellow from the Kolling Institute and University of Sydney Royal North Shore Hospital, Dr. Cindy Shu is joining Regeneus for a 12-month project focused on readying Progenza™ for Phase II trials in Japan and the U.S.
A Medical Research Future Fund initiative, the grant provides financial support to Australian, international and/or multinational medical technology and pharmaceutical comp
Q. What is your background and experience in the regenerative medicine and stem cell space? How did this lead you to Regeneus?
A. I have always had a passion to play a part in improving people’s health and this passion led me to undertaking a Bachelor’s degree of Medical Science at The University of Technology, Sydney (UTS).
It was actually Regeneus that led me into the stem cell and regenerative medicine space – not the other w
Q. How did you develop your interest in the regenerative medicine and stem cell space?
A. Born and raised in Indonesia, where the curriculum was quite focused on science, I have always been intrigued in life sciences and everything related.
I came to Australia for university in 2008 and completed a Bachelor of Biotechnology at the University of New South Wales (UNSW). While there was a myriad of biotech fields covered during my study, my interest piqued at ste
Q. Tell us about your role as a Research Scientist and Project Lead at Regeneus?
A. My role is extremely diverse and has evolved over my time at Regeneus. Initially, I was responsible for optimising our product manufacturing processes, including manufacturing products for our preclinical and clinical trials. For example, I provided the data to support preclinical studies that evaluated Progenza™ for osteoarthritis in rabbits and pain in rats.
Q. Tell us about your role as Chief Scientific Officer at Regeneus?
A. My role at Regeneus from the beginning has been to invent and develop Regeneus’ intellectual property (IP). With over 30 years’ experience as a scientific researcher spanning fields of regenerative medicine and microbiology, I have always been focused on developing and licencing technologies to solve problems.
When I co-founded Regeneus in 2008, we knew it was impo
Regeneus is excited to announce it is partnering with the Australian Department of Defence to develop its platform stem cell bioactive secretome technology Sygenus for combat casualty care. As part of the grant, Regeneus will receive $300k in funding to optimise the Sygenus formulation to treat combat casualties, including conducting Sygenus’ first in human study on pain.